• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical trial participant ’s autopsy and brain exam stoke Alzheimer’s drug fears
A full autopsy and detailed examination of the brain of a 79-year-old Florida woman who died after receiving lecanemab, an experimental Alzheimer’s therapy, in a pivotal clinical trial has deepened some researchers’ concerns that it poses serious risks for patients who share the woman’s hard-to-diagnose, preexisting condition. The patient’s history and autopsy “strongly suggests that lecanemab infusions were a catalyst leading to the events resulting in her death,” says Vanderbilt University pathologist Hannah Harmsen, co-author of a recently completed case report, which Science has obtained. The aut...
Source: Science of Aging Knowledge Environment - April 13, 2023 Category: Geriatrics Source Type: research

Scientists tie third clinical trial death to experimental Alzheimer ’s drug
As enthusiasm mounts for a new experimental antibody that appears to slow cognitive decline in some Alzheimer’s patients, a third death linked to the drug during its clinical testing may amplify concerns about its safety. Science has obtained medical records showing a 79-year-old Florida woman participating in an ongoing trial of the antibody died in mid-September after experiencing extensive brain swelling and bleeding, as well as seizures. Multiple neuroscientists who reviewed the records at Science ’s request believe her death was likely caused by the antibody, lecanemab. “The brain swelling and t...
Source: ScienceNOW - December 21, 2022 Category: Science Source Type: news

Second death linked to potential antibody treatment for Alzheimer ’s disease
A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug. The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators. The woman, who received infusions of the antibody as part of the trial, s...
Source: ScienceNOW - November 28, 2022 Category: Science Source Type: news

The Clinical and Neuropathological Correlates of Second-Impact Syndrome: Case Report of a 17-year-old Female Rugby Player (P6.164)
Conclusions:This is the first case study to report the clinical and neuropathological features of SIS. Larger autopsy samples are needed to systematically identify clinicopathological correlates of SIS to facilitate research on risk factors and preventative strategies (e.g., return-to-play guidelines) to prevent unnecessary fatalities in young athletes.Study Supported by: This work was supported by the National Institute of Neurological Disorders and Stroke (1U01NS086659-01, U01NS093334, R01NS078337, R56NS078337), Department of Defense (W81XWH-13-2-0064), Department of Veterans Affairs, the Veterans Affairs Biorepository (...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Mian, M., Alosco, M., Mez, J., Kiernan, P., Daneshvar, D., Nowinski, C., Kowall, N., Stern, R., Katz, D., Cantu, R., McKee, A. Tags: Neuro Trauma and Sports Neurology II Source Type: research